GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (NAS:ALNY) » Definitions » Gross Margin %

ALNY (Alnylam Pharmaceuticals) Gross Margin % : 82.85% (As of Sep. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Alnylam Pharmaceuticals Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Alnylam Pharmaceuticals's Gross Profit for the three months ended in Sep. 2024 was $415 Mil. Alnylam Pharmaceuticals's Revenue for the three months ended in Sep. 2024 was $501 Mil. Therefore, Alnylam Pharmaceuticals's Gross Margin % for the quarter that ended in Sep. 2024 was 82.85%.

Warning Sign:

Alnylam Pharmaceuticals Inc gross margin has been in long-term decline. The average rate of decline per year is -2.8%.


The historical rank and industry rank for Alnylam Pharmaceuticals's Gross Margin % or its related term are showing as below:

ALNY' s Gross Margin % Range Over the Past 10 Years
Min: 83.02   Med: 83.95   Max: 97.59
Current: 85.37


During the past 13 years, the highest Gross Margin % of Alnylam Pharmaceuticals was 97.59%. The lowest was 83.02%. And the median was 83.95%.

ALNY's Gross Margin % is ranked better than
80.72% of 747 companies
in the Biotechnology industry
Industry Median: 60.58 vs ALNY: 85.37

Alnylam Pharmaceuticals had a gross margin of 82.85% for the quarter that ended in Sep. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Alnylam Pharmaceuticals was -2.80% per year.


Alnylam Pharmaceuticals Gross Margin % Historical Data

The historical data trend for Alnylam Pharmaceuticals's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals Gross Margin % Chart

Alnylam Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 88.60 84.16 83.40 83.73 83.02

Alnylam Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 88.77 80.47 86.65 89.59 82.85

Competitive Comparison of Alnylam Pharmaceuticals's Gross Margin %

For the Biotechnology subindustry, Alnylam Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alnylam Pharmaceuticals's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's Gross Margin % falls into.



Alnylam Pharmaceuticals Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Alnylam Pharmaceuticals's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=1517.9 / 1828.292
=(Revenue - Cost of Goods Sold) / Revenue
=(1828.292 - 310.406) / 1828.292
=83.02 %

Alnylam Pharmaceuticals's Gross Margin for the quarter that ended in Sep. 2024 is calculated as


Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=415 / 500.919
=(Revenue - Cost of Goods Sold) / Revenue
=(500.919 - 85.905) / 500.919
=82.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Alnylam Pharmaceuticals  (NAS:ALNY) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Alnylam Pharmaceuticals had a gross margin of 82.85% for the quarter that ended in Sep. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Alnylam Pharmaceuticals Gross Margin % Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alnylam Pharmaceuticals Business Description

Address
675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Executives
Tolga Tanguler officer: EVP, Chief Commercial Officer 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE MA 02142
Yvonne Greenstreet officer: EVP, Chief Commercial Officer PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, PARSIPPANY NJ 07054
Jeffrey V. Poulton officer: Chief Financial Officer 300 THIRD STREET, CAMBRIDGE MA 02142
Pushkal Garg officer: CMO & EVP Dev & Med Affairs C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Dennis A Ausiello director PFIZER INC ATTN CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Amy W Schulman director PFIZER INC. ATTN: CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Pyott David E I director C/O ALLERGAN, 2525 DUPONT DRIVE, IRVINE CA 92612
Phillip A Sharp director BIOGEN INC LEGAL DEPARTMENT, 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Indrani Lall Franchini officer: EVP, CLO & Secretary C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
Michael W Bonney director 65 HAYDEN AVE, LEXINGTON MA 02421
Akshay Vaishnaw officer: SVP, Clinical Research 300 THIRD STREET, CAMBRIDGE MA 02139
Peter N Kellogg director MERCK & CO., INC, ONE MERCK DRIVE., P.O. BOX 100, WHITEHOUSE STATION NJ 08889-0100
Carolyn R Bertozzi director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Charles Elliott Sigal director 32 BREARLY ROAD, PRINCETON NJ 08540
John Maraganore director, officer: President and CEO 75 SIDNEY ST, CAMBRIDGE MA 02139